登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688271 证券简称：联影医疗 公告编号：2025-047 上海联影医疗科技股份有限公司 关于持股5%以上的股东减持股份结果暨 减持至5%以下的权益变动提示性公告 投资者及其一致行动人宁波梅山保税港区影聚投资管理合伙企业（有限合伙）、宁波梅山保税港区影力 投资管理合伙企业（有限合伙）、宁波梅山保税港区影健投资管理合伙企业（有限合伙）、宁波梅山保 税港区影康投资管理合伙企业（有限合伙）、上海影董企业管理合伙企业（有限合伙）保证向本公司提 供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 本次权益变动属于公司首次公开发行持股5%以上股东实施已披露的股份减持计划，不触及要约收 购。 ● 本次权益变动后，股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）（以下简称"宁波影 聚"）、宁波梅山保税港区影力投资管理合伙企业（有限合伙）（以下简称"宁波影力"）、宁波梅山保 税港区影健投资管理合伙企业（有限合伙）（以下简称"宁波影健"）、宁波梅山保税港区影康投资管 ...

联影医疗11月19日大宗交易平台共发生2笔成交，合计成交量789.86万股，成交金额9.87亿元。成交价格 均为125.00元，相对今日收盘价折价4.66%。 进一步统计，近3个月内该股累计发生4笔大宗交易，合计成交金额为9.98亿元。 11月19日联影医疗大宗交易一览 | 成交量 （万股） | 成交金额 | 成交价格 | 相对当日收盘折 溢价（%） | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | | （万元） | （元） | | | | | 710.87 | 88858.63 | 125.00 | -4.66 | 中国国际金融股份有限 | 中国中金财富证券有限 | | | | | | 公司上海分公司 | 公司上海分公司 | | 78.99 | 9873.19 | 125.00 | -4.66 | 中国国际金融股份有限 | 中国中金财富证券有限 | | | | | | 公司上海分公司 | 公司上海分公司 | （文章来源：证券时报网） 证券时报·数据宝统计显示，联影医疗今日收盘价为131.11元，下跌2.34%，日换手率为0.40%，成交额 为 ...

上市公司名称：上海联影医疗科技股份有限公司 股票简称：联影医疗 股票代码：688271 股票上市地点：上海证券交易所 信息披露义务人1：宁波梅山保税港区影聚投资管理合伙企业（有限合伙） 住所及通讯地址：浙江省宁波市北仑区梅山七星路88号1幢401室A区C1122 信息披露义务人2：宁波梅山保税港区影力投资管理合伙企业（有限合伙） 住所及通讯地址：浙江省宁波市北仑区梅山七星路88号1幢401室A区C1124 信息披露义务人3：宁波梅山保税港区影健投资管理合伙企业（有限合伙） 住所及通讯地址：浙江省宁波市北仑区梅山七星路88号1幢401室A区C1121 信息披露义务人4：宁波梅山保税港区影康投资管理合伙企业（有限合伙） 住所及通讯地址：浙江省宁波市北仑区梅山七星路88号1幢401室A区C1123 信息披露义务人5：上海影董企业管理合伙企业（有限合伙） 住所及通讯地址：上海市崇明区竖新镇响椿路58号西四楼319室（上海竖新经济 开发区） 股份变动性质：股份减少（集中竞价及大宗交易） 1 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证 券法》、《上市公司收购管理办法》、《公开发行证券的公司信息披露 ...

上海联影医疗科技股份有限公司关于持股 5%以上的股东 减持股份结果暨减持至 5%以下的权益变动提示性公告 投资者及其一致行动人宁波梅山保税港区影聚投资管理合伙企业（有限合 伙）、宁波梅山保税港区影力投资管理合伙企业（有限合伙）、宁波梅山保税港区 影健投资管理合伙企业（有限合伙）、宁波梅山保税港区影康投资管理合伙企业 （有限合伙）、上海影董企业管理合伙企业（有限合伙）保证向本公司提供的信 息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次权益变动属于公司首次公开发行持股 5%以上股东实施已披露的股 份减持计划，不触及要约收购。 证券代码：688271 证券简称：联影医疗 公告编号：2025-047 本次权益变动后，股东宁波梅山保税港区影聚投资管理合伙企业（有限 合伙）（以下简称"宁波影聚"）、宁波梅山保税港区影力投资管理合伙企业（有 限合伙）（以下简称"宁波影力"）、宁波梅山保税港区影健投资管理合伙企业（有 限合伙）（以下简称"宁波影健"）、宁波梅山保税港区影康投资管理合伙企业（有 限合伙）（以下简称"宁波影康"）、 ...

Core Viewpoint - The stock of United Imaging Healthcare (688271) has experienced a decline, with a closing price of 131.11 yuan on November 19, 2025, down by 2.34% [1] Group 1: Stock Performance - On November 19, 2025, the stock had a turnover rate of 0.4%, with a trading volume of 32,800 hands and a transaction amount of 435 million yuan [1] - The net outflow of main funds was 14.797 million yuan, accounting for 3.4% of the total transaction amount, while retail investors saw a net outflow of 36.92 thousand yuan, representing 0.08% of the total [1][2] Group 2: Financial Metrics - As of the third quarter of 2025, United Imaging Healthcare reported a main business revenue of 8.859 billion yuan, a year-on-year increase of 27.39%, and a net profit attributable to shareholders of 1.12 billion yuan, up 66.91% [3] - The company’s gross profit margin stands at 47.02%, while the net profit margin is 12.44% [3] Group 3: Industry Comparison - United Imaging Healthcare's total market capitalization is 108.055 billion yuan, significantly higher than the industry average of 11.279 billion yuan, ranking 2nd in the industry [3] - The company has a price-to-earnings ratio of 72.34, which is higher than the industry average of 56.7, ranking 64th in the industry [3] Group 4: Analyst Ratings - In the past 90 days, 27 institutions have rated the stock, with 20 buy ratings and 7 hold ratings, and the average target price set by institutions is 175.45 yuan [4]

Core Insights - Chinese enterprises are experiencing a new wave of globalization, with a focus on expanding into overseas markets and enhancing their core technologies, exemplified by the recent launch of the uSONIQUE ultrasound series by United Imaging Healthcare [2][3] - The role of CFOs is evolving, requiring them to develop capabilities in global resource allocation, data-driven strategic judgment, and compliance under international regulations [2] - The global landscape is shifting from a developed-country-centric model to a more decentralized and sustainable collaborative structure, presenting both opportunities and challenges for Chinese companies [4] Company Developments - United Imaging Healthcare plans to launch its full line of ultrasound products in both domestic and international markets, with ongoing applications for CE and FDA certifications [3] - The ultrasound equipment market in China is projected to grow from 9.02 billion in 2020 to 21.62 billion by 2030, with a compound annual growth rate of 8.1% [3] - Despite the growth potential, the high-end ultrasound market remains dominated by foreign companies, with domestic market share below 40% [3] Industry Trends - Chinese enterprises are undergoing a deep restructuring phase characterized by three transformations: cognitive, operational, and strategic [4] - The expansion of Chinese companies is marked by significant growth in direct foreign investment and mergers and acquisitions, with diverse practices including brand development and technological integration [4] - The challenges faced by companies in their internationalization efforts include supply chain restructuring, geopolitical tensions, rapid technological changes, and complex compliance regulations [6][8] Financial Management Evolution - The role of CFOs is shifting from traditional financial management to becoming Chief Value Officers, emphasizing the importance of sustainability and long-term value creation [6] - The financial management landscape is expected to undergo significant changes, including the rise of AI in accounting and a focus on ESG reporting [7] - Companies must balance cost optimization with compliance management to enhance the sustainability and resilience of their global supply chains [8]

Core Viewpoint - The stock of United Imaging Healthcare has experienced fluctuations, with a recent decline of 2.00% and a total market capitalization of 108.43 billion yuan, reflecting a mixed performance in the stock market [1]. Financial Performance - For the period from January to September 2025, United Imaging Healthcare reported a revenue of 8.859 billion yuan, representing a year-on-year growth of 27.39%, and a net profit attributable to shareholders of 1.120 billion yuan, which is a 66.91% increase compared to the previous year [2]. - The company has distributed a total of 641 million yuan in dividends since its A-share listing [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for United Imaging Healthcare increased to 32,400, marking a 96.28% rise from the previous period, while the average number of circulating shares per person decreased by 29.23% to 25,444 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited holding 19.036 million shares, a decrease of 2.9809 million shares from the previous period [3].

截至2025年11月18日收盘，联影医疗(688271)报收于134.25元，上涨0.19%，换手率0.5%，成交量4.08万 手，成交额5.44亿元。 当日关注点 公司公告汇总 联影医疗持股5%以上股东宁波梅山保税港区影聚投资管理合伙企业（有限合伙）、宁波梅山保税港区 影力投资管理合伙企业（有限合伙）及其一致行动人于2025年9月1日至11月14日期间通过集中竞价方式 合计减持公司股份5,478,055股，占公司总股本的0.66%。本次权益变动后，上述股东合计持股比例由 6.62%下降至5.96%，权益变动触及1%刻度。本次减持为履行已披露的减持计划，不触及要约收购，不 会导致公司控股股东及实际控制人发生变化，对公司治理结构及持续经营无重大影响。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：11月18日主力资金净流出3508.96万元，占总成交额6.46%。 来自公司公告汇总：联影医疗持股5%以上股东及其一致行动人减持5,478,055股，持股比例由 6.62%降至5.96%，权益变动触及1%刻度。 交易信息 ...

Group 1 - The company announced the election of Mr. Zhang Yue as the chairman [2]

Core Points - The company announced the convening of its fifth board meeting on November 18, 2025, to review the proposal for granting restricted stock to incentive recipients [1] - The grant date is set for November 18, 2025, with a grant price of 17.00 yuan per share [1] - A total of 3,275,264 shares of restricted stock will be granted to 110 incentive recipients [1]